Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
14.54
+0.18 (1.25%)
At close: Mar 28, 2025, 4:00 PM
14.53
-0.01 (-0.05%)
After-hours: Mar 28, 2025, 7:56 PM EDT
Cartesian Therapeutics Revenue
In the year 2024, Cartesian Therapeutics had annual revenue of $38.91M with 49.64% growth. Cartesian Therapeutics had revenue of $-759.00K in the quarter ending December 31, 2024, a decrease of -109.18%.
Revenue (ttm)
$38.91M
Revenue Growth
+49.64%
P/S Ratio
6.46
Revenue / Employee
$589,591
Employees
66
Market Cap
376.69M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 38.91M | 12.91M | 49.64% |
Dec 31, 2023 | 26.00M | -84.77M | -76.53% |
Dec 31, 2022 | 110.78M | 25.70M | 30.21% |
Dec 31, 2021 | 85.08M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRNAC News
- 24 days ago - Cartesian Therapeutics Announces New Employment Inducement Grant - GlobeNewsWire
- 5 weeks ago - Cartesian Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 2 months ago - Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis - GlobeNewsWire
- 4 months ago - Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial - GlobeNewsWire
- 4 months ago - Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit - GlobeNewsWire
- 5 months ago - Cartesian Therapeutics: Uncertainty Remains - Seeking Alpha
- 5 months ago - Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting - GlobeNewsWire